BRPI0918966A2 - inibidores de protease - Google Patents

inibidores de protease

Info

Publication number: BRPI0918966A2
Authority: BR; Brazil
Prior art keywords: protease inhibitors; protease; inhibitors
Prior art date: 2008-09-24

Application number

BRPI0918966A

Other languages

English (en)

Inventor

Bertil Samuelsson

Lourdes Salvadore Odén

Magnus Nilsson

Pia Kahnberg

Urszula Grabowska

Original Assignee

Medivir Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-24

Filing date

2009-09-24

Publication date

2015-12-01

2009-09-24 Application filed by Medivir Ab filed Critical Medivir Ab

2015-12-01 Publication of BRPI0918966A2 publication Critical patent/BRPI0918966A2/pt

2020-02-18 Publication of BRPI0918966A8 publication Critical patent/BRPI0918966A8/pt

2020-03-03 Publication of BRPI0918966B1 publication Critical patent/BRPI0918966B1/pt

2021-05-25 Publication of BRPI0918966B8 publication Critical patent/BRPI0918966B8/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Neurology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BRPI0918966A 2008-09-24 2009-09-24 composto inibidor de protease, composição farmacêutica compreendendo dito composto e uso terapêutico do mesmo BRPI0918966B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0817424.5A GB0817424D0 (en)	2008-09-24	2008-09-24	Protease inhibitors
GB0817424.5		2008-09-24
PCT/EP2009/062406 WO2010034788A1 (en)	2008-09-24	2009-09-24	Protease inhibitors

Publications (4)

Publication Number	Publication Date
BRPI0918966A2 true BRPI0918966A2 (pt)	2015-12-01
BRPI0918966A8 BRPI0918966A8 (pt)	2020-02-18
BRPI0918966B1 BRPI0918966B1 (pt)	2020-03-03
BRPI0918966B8 BRPI0918966B8 (pt)	2021-05-25

Family

ID=39952074

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0918966A BRPI0918966B8 (pt)	2008-09-24	2009-09-24	composto inibidor de protease, composição farmacêutica compreendendo dito composto e uso terapêutico do mesmo

Country Status (22)

Country	Link
US (11)	US8242119B2 (pt)
EP (1)	EP2331548B1 (pt)
JP (1)	JP5639592B2 (pt)
KR (1)	KR101671177B1 (pt)
CN (2)	CN103992329B (pt)
AU (1)	AU2009295898B2 (pt)
BR (1)	BRPI0918966B8 (pt)
CA (1)	CA2738023C (pt)
CY (1)	CY1114833T1 (pt)
DK (1)	DK2331548T3 (pt)
EA (1)	EA020122B1 (pt)
ES (1)	ES2438095T3 (pt)
GB (1)	GB0817424D0 (pt)
HR (1)	HRP20131131T1 (pt)
IL (1)	IL211811A (pt)
MY (1)	MY152969A (pt)
PL (1)	PL2331548T3 (pt)
PT (1)	PT2331548E (pt)
RS (1)	RS53054B (pt)
SI (1)	SI2331548T1 (pt)
WO (2)	WO2010034788A1 (pt)
ZA (1)	ZA201102179B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0817424D0 (en)	2008-09-24	2008-10-29	Medivir Ab	Protease inhibitors
GB201314503D0 (en) *	2013-08-13	2013-09-25	Medivir Ab	Cysteine protease inhibitor salt
CN107286150B (zh) *	2016-04-11	2020-07-07	中国科学院上海有机化学研究所	N-杂环类化合物、其中间体、制备方法、药物组合物和应用
AU2020250933A1 (en)	2019-04-05	2021-10-28	Centre Hospitalier Régional Et Universitaire De Brest	Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
CN110563611B (zh) *	2019-09-19	2021-02-02	中国医学科学院医药生物技术研究所	一种异羟肟酸类衍生物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR013079A1 (es) *	1997-05-06	2000-12-13	Smithkline Beecham Corp	Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
JP3102101U (ja)	2003-12-05	2004-07-02	株式会社ライトボーイ	投光機
CA2548600A1 (en)	2003-12-12	2005-06-23	Merck Frosst Canada & Co.	Cathepsin cysteine protease inhibitors
SE0400022D0 (sv) *	2004-01-08	2004-01-08	Medivir Ab	New compounds
BRPI0506719A (pt)	2004-01-08	2007-05-02	Medivir Ab	composto, composição farmacêutica, e, uso de um composto
FR2889701B1 (fr)	2005-08-12	2007-10-05	Sanofi Aventis Sa	Derives de 5-pyridinyl-1-azabicyclo[3.2.1]octane, leur preparation en therapeutique.
GB0614044D0 (en) *	2006-07-14	2006-08-23	Amura Therapeutics Ltd	Compounds
GB0614042D0 (en)	2006-07-14	2006-08-23	Amura Therapeutics Ltd	Compounds
WO2008114054A1 (en) *	2007-03-19	2008-09-25	Medivir Ab	Protease inhibitors
US7893067B2 (en) *	2007-06-27	2011-02-22	Medivir Ab	Cysteine protease inhibitors
WO2009087379A2 (en)	2008-01-09	2009-07-16	Amura Therapeutics Limited	Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
GB0817424D0 (en) *	2008-09-24	2008-10-29	Medivir Ab	Protease inhibitors

2008
- 2008-09-24 GB GBGB0817424.5A patent/GB0817424D0/en not_active Ceased
2009
- 2009-09-24 RS RS20130522A patent/RS53054B/sr unknown
- 2009-09-24 CN CN201410205405.9A patent/CN103992329B/zh active Active
- 2009-09-24 AU AU2009295898A patent/AU2009295898B2/en active Active
- 2009-09-24 SI SI200930786T patent/SI2331548T1/sl unknown
- 2009-09-24 KR KR1020117009274A patent/KR101671177B1/ko active Active
- 2009-09-24 WO PCT/EP2009/062406 patent/WO2010034788A1/en not_active Ceased
- 2009-09-24 WO PCT/EP2009/062408 patent/WO2010034790A1/en not_active Ceased
- 2009-09-24 JP JP2011528326A patent/JP5639592B2/ja active Active
- 2009-09-24 HR HRP20131131AT patent/HRP20131131T1/hr unknown
- 2009-09-24 CN CN200980148042.7A patent/CN102224156B/zh active Active
- 2009-09-24 BR BRPI0918966A patent/BRPI0918966B8/pt active IP Right Grant
- 2009-09-24 MY MYPI20111288 patent/MY152969A/en unknown
- 2009-09-24 US US12/739,489 patent/US8242119B2/en active Active
- 2009-09-24 CA CA2738023A patent/CA2738023C/en active Active
- 2009-09-24 EA EA201170479A patent/EA020122B1/ru not_active IP Right Cessation
- 2009-09-24 PL PL09783391T patent/PL2331548T3/pl unknown
- 2009-09-24 ES ES09783391.7T patent/ES2438095T3/es active Active
- 2009-09-24 DK DK09783391.7T patent/DK2331548T3/da active
- 2009-09-24 EP EP09783391.7A patent/EP2331548B1/en active Active
- 2009-09-24 PT PT97833917T patent/PT2331548E/pt unknown
2011
- 2011-03-17 IL IL211811A patent/IL211811A/en active IP Right Grant
- 2011-03-23 ZA ZA2011/02179A patent/ZA201102179B/en unknown
2012
- 2012-07-03 US US13/541,519 patent/US8426421B2/en active Active
2013
- 2013-03-14 US US13/831,267 patent/US8735395B2/en active Active
- 2013-11-18 CY CY20131101021T patent/CY1114833T1/el unknown
2014
- 2014-04-09 US US14/249,332 patent/US9200006B2/en active Active
2015
- 2015-11-13 US US14/940,817 patent/US9428517B2/en active Active
2016
- 2016-08-25 US US15/247,804 patent/US20170166538A1/en not_active Abandoned
2017
- 2017-08-02 US US15/667,292 patent/US20170334867A1/en not_active Abandoned
2018
- 2018-03-30 US US15/941,947 patent/US10329266B2/en not_active Expired - Fee Related
2019
- 2019-06-24 US US16/449,850 patent/US10723709B2/en not_active Expired - Fee Related
2020
- 2020-07-27 US US16/940,067 patent/US11312693B2/en active Active
2022
- 2022-04-25 US US17/728,943 patent/US12378209B2/en active Active

Also Published As

Publication number	Publication date
EP2331548A1 (en)	2011-06-15
HK1152522A1 (en)	2012-03-02
RS53054B (sr)	2014-04-30
US11312693B2 (en)	2022-04-26
PL2331548T3 (pl)	2014-03-31
US8735395B2 (en)	2014-05-27
US20210017140A1 (en)	2021-01-21
GB0817424D0 (en)	2008-10-29
US20180327371A1 (en)	2018-11-15
US20120289519A1 (en)	2012-11-15
EP2331548B1 (en)	2013-09-04
US8426421B2 (en)	2013-04-23
WO2010034790A1 (en)	2010-04-01
US10329266B2 (en)	2019-06-25
US20160068539A1 (en)	2016-03-10
US20140221654A1 (en)	2014-08-07
US12378209B2 (en)	2025-08-05
US20110039862A1 (en)	2011-02-17
KR101671177B1 (ko)	2016-11-01
SI2331548T1 (sl)	2014-02-28
JP2012503625A (ja)	2012-02-09
US10723709B2 (en)	2020-07-28
US20130231349A1 (en)	2013-09-05
US20200010434A1 (en)	2020-01-09
CN103992329A (zh)	2014-08-20
CN103992329B (zh)	2016-08-17
BRPI0918966A8 (pt)	2020-02-18
US20220332690A1 (en)	2022-10-20
CN102224156A (zh)	2011-10-19
US9200006B2 (en)	2015-12-01
MY152969A (en)	2014-12-15
EA201170479A1 (ru)	2011-12-30
PT2331548E (pt)	2013-12-10
ZA201102179B (en)	2011-12-28
CA2738023C (en)	2017-03-07
BRPI0918966B1 (pt)	2020-03-03
AU2009295898B2 (en)	2012-06-28
CA2738023A1 (en)	2010-04-01
AU2009295898A1 (en)	2010-04-01
US20170334867A1 (en)	2017-11-23
BRPI0918966B8 (pt)	2021-05-25
WO2010034788A1 (en)	2010-04-01
HRP20131131T1 (hr)	2014-01-17
CN102224156B (zh)	2014-06-25
KR20110061632A (ko)	2011-06-09
IL211811A (en)	2014-01-30
US20170166538A1 (en)	2017-06-15
CY1114833T1 (el)	2016-12-14
ES2438095T3 (es)	2014-01-15
JP5639592B2 (ja)	2014-12-10
US8242119B2 (en)	2012-08-14
DK2331548T3 (da)	2013-12-16
IL211811A0 (en)	2011-06-30
US9428517B2 (en)	2016-08-30
EA020122B1 (ru)	2014-08-29

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-06-11	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-12-03	B06I	Publication of requirement cancelled [chapter 6.9 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 6.1 NA RPI NO 2542 DE 24/09/2019 POR TER SIDO INDEVIDA.
2020-02-04	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-03-03	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/03/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

Publication	Publication Date	Title
CY2020024I2 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
NO2020045I1 (no)	2020-12-17	Luspatercept
LTC2178888I2 (lt)	2018-03-12	Proteazomos inhibitoriai
BRPI0807547A2 (pt)	2014-06-17	Inibidores de aspartil protease hetercíclicos
EP2305306A4 (en)	2012-08-29	NEURO INVASION INHIBITOR
BRPI0917808A2 (pt)	2019-09-24	inibidores de cmet
BRPI0814797A2 (pt)	2015-02-03	Inibidores dna-pk
CR10831A (es)	2009-06-18	INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2041138T3 (da)	2014-08-11	Pyrroltriazinkinase-inhibitorer
BRPI0918564A2 (pt)	2015-12-01	inibidores
DK2024375T3 (da)	2011-06-27	Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
BRPI1011267A2 (pt)	2016-03-22	inibidores de protease
EP2374802A4 (en)	2012-06-20	INHIBITOR OF KYNURENINE PRODUCTION
DK2066662T3 (da)	2013-01-07	Serinhydrolaseinhibitorer
EP2435048A4 (en)	2013-07-10	RADIOACTIVELY MARKED PDE10 HEMMER
DK2240506T3 (da)	2013-04-08	IAP inhibitorer
BRPI0922283A2 (pt)	2015-12-29	inibidores da cistéina protease
EP2313426A4 (en)	2012-01-18	NEW PROTEASE INHIBITORS
DK2331548T3 (da)	2013-12-16	Proteasehæmmere
ATE522533T1 (de)	2011-09-15	Pyrazolopyrimidinonkinaseinhibitor
BRPI0919073A2 (pt)	2016-03-15	inibidores de protease
FI20075320A0 (fi)	2007-05-07	Uusia käyttökelpoisia inhibiittoreita
TH0801000834A (th)	2016-11-15	ตัวยับยั้งเฮเทอโรไซคลิก แอสพาร์ทิลโปรตีเอส